Oxford BioMedica Block listing Application

RNS Number : 2735R
Oxford Biomedica PLC
25 June 2015



Oxford BioMedica

Block listing Application


Oxford, UK - 25 June 2014: Oxford BioMedica plc ("OXB" or "the Group") (LSE: OXB), a leading gene and cell therapy group, announces that application has been made to the Financial Conduct Authority and the London Stock Exchange for admission to (i) the Premium segment of the Official List and (ii) to trading on the London Stock Exchange's markets for a block listing of securities totalling 22 million ordinary shares of 1 pence each (the "Ordinary Shares").


The Ordinary Shares are being reserved under a block listing and will be issued from time to time pursuant to the Group's LTIP.


It is expected that admission of the Ordinary Shares will become effective on 26 June 2015. The Ordinary Shares will rank pari passu in all respects with the Group's existing ordinary shares in issue.



- Ends -



For further information, please contact:



Oxford BioMedica plc:

John Dawson, Chief Executive Officer

Tim Watts, Chief Financial Officer


Tel: +44 (0)1865 783 000


Consilium Strategic Communications

Mary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton




Tel: +44 (0)20 3709 5700


Notes for editors


About Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy Group with an unrivalled portfolio of gene therapy products in development and a platform of exclusive and pioneering technologies with which it designs, develops and manufactures unique gene-based medicines for some of world's largest pharmaceutical companies. Leveraging its proprietary LentiVector® IP and gene delivery system technology platform and unique tumour antigen (5T4), Oxford BioMedica is advancing its pipeline of seven gene therapy products addressing diseases for which there are currently no treatments or that

are inadequately treated today, including ocular and central nervous system disorders. OXB Solutions, the Group's industry-leading manufacturing and development business, provides services to collaborators and partners working in gene and cell therapy, including Novartis and Immune Design Corp.  In addition, the Group has licenced products and IP to Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk  and www.oxbsolutions.co.uk.


This information is provided by RNS
The company news service from the London Stock Exchange